Abstract

NOD-like receptor (NLR) NLRP3 inflammasome activation has been implicated in the progression of non-alcoholic fatty liver disease (NAFLD) from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH). It has been also shown that palmitic acid (PA) activates NLRP3 inflammasome and promotes interleukin-1β (IL-1β) secretion in Kupffer cells (KCs). However, the specific mechanism of the NLRP3 inflammasome activation is unclear. We studies the molecular mechanisms by investigating the roles of Thioredoxin-interacting protein (TXNIP) and NLRP3 on NAFLD development in patients, high-fat diet (HFD)-induced NAFL and methionine choline deficient (MCD) diet-induced NASH in wild type (WT), TXNIP−/− (thioredoxin-interacting protein) and NLRP3−/− mice, and isolated KCs. We found that the expressions of NLRP3 and TXNIP in human liver tissues were higher in NASH group than in NAFL group. Furthermore, co-immunoprecipitation analyses show that activation of the TXNIP-NLRP3 inflammasome protein complex occurred in KCs of NASH WT mice rather than NAFL WT mice, thus suggesting that the formation and activation of this protein complex is mainly involved in the development of NASH. NLRP3−/− mice exhibited less severe NASH than WT mice in MCD diet model, whereas TXNIP deficiency enhanced NLRP3 inflammasome activation and exacerbated liver injury. PA triggered the activation and co-localization of the NLRP3 inflammasome protein complex in KCs isolated from WT and TXNIP−/− but not NLRP3−/− mice, and most of the complex co-localized with mitochondria of KCs following PA stimulation. Taken together, our novel findings indicate that TXNIP plays a protective and anti-inflammatory role in the development of NAFLD through binding and suppressing NLRP3.

Highlights

  • Non-alcoholic fatty liver disease (NAFLD) is considered to be the main hepatic manifestation of metabolic syndrome, and is currently the most common cause of chronic liver disease in many developed and developing countries worldwide [1, 2]

  • There were no significant differences in alanine aminotransferase (ALT), aspartate transaminase (AST) and triglyceride (TG) levels among the groups, whereas the serum levels of free fatty acid (FFA) and IL-1β were significantly higher in the non-alcoholic steatohepatitis (NASH) patients compared with the normal healthy controls and non-alcoholic fatty liver (NAFL) patients, suggesting that the FFA and IL-1β levels are mainly associated with NASH but not NAFL

  • We found that FFA, as a mechanistic activator of NLRP3 inflammasome, activated NLRP3 inflammasome and induced IL-1β secretion in Kupffer cells (KCs) and that the expression of NLRP3 increased in liver tissues and was accompanied by elevated levels of FFA and IL-1β in serum of NASH patients and methionine choline deficient (MCD) induced mice model

Read more

Summary

Introduction

Non-alcoholic fatty liver disease (NAFLD) is considered to be the main hepatic manifestation of metabolic syndrome, and is currently the most common cause of chronic liver disease in many developed and developing countries worldwide [1, 2]. NAFLD ranges from hepatic steatosis or non-alcoholic fatty liver (NAFL), which is characterized by the accumulation of triglycerides in hepatocytes, to non-alcoholic steatohepatitis (NASH), which can eventually progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma [1, 3]. Day and James in 1998 [4] According to this theory, the initial hepatocellular lipid accumulation represents the ‘first hit’, followed by a “second hit”, in which pro-inflammatory mediators induce inflammation and hepatocellular injury, promoting the progression to NASH. It is currently thought that the genesis and development of NASH are closely related to metaflammation, a low-grade form of chronic inflammation that is mainly involved in the “second hit” [6]. The exact mechanism underlying the development of NASH remains to be clearly defined

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call